Pliant Therapeutics' GAAP loss for 6M 2021 was $45.687 million, up 7.65 times from $5.972 million in the previous year. Revenue declined 8.2 times to $3.963 million from $32.538 million a year earlier.
Pliant Therapeutics' GAAP loss for 6M 2021 was $45.687 million, up 7.65 times from $5.972 million in the previous year. Revenue declined 8.2 times to $3.963 million from $32.538 million a year earlier. 
ir.pliantrx.com
English (US) 